The market is projected to grow to USD 382.59 million by 2032, exhibiting a Compound Annual Growth Rate (CAGR) of 6.25%. While the market remains smaller than broader autoimmune sectors, its high value is driven by the intensive, long-term nature of treatment—particularly for patients suffering from chronic pulmonary complications. https://livepositively.com/unlocking-value-pricing-regulatory-landscape-and-future-forecast-for-the-ocular-bromfenac-market-2025-2032/